HEPA Hepion Pharmaceuticals, Inc. - 8-K

Item 5.02

Departure
of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers .

On
March 16, 2026, Dr. Kaouthar Lbiati, the Chief Executive Officer of Hepion Pharmaceuticals, Inc. (the “Company”) informed
the Board of Directors (the “Board”) of the Company that she was resigning as Chief Executive Officer for personal reasons,
effective immediately.

On
March 16, 2026, the Board approved the appointment of Gary Stetz as interim Chief Executive Officer of the Company and director and appointed
Vincent LoPriore as Executive Chairman, Sireesh Appajosyula as director and Chase LoPriore as director.

There
are no arrangements or understandings between Messrs. Stetz, V. LoPriore, Appajosyula and C. LoPriore and any other person pursuant to
which such person was selected as an officer or director of the Company, as the case may be, and there is no family relationship between
any of Mr. Stetz, Mr. V. LoPriore, Mr. Appajosyula and Mr. C. LoPriore and any of the Company’s other directors or executive officers.

- 2 -